IP Library Granted Patent US 11,497,198
Granted Patent B2
US 11,497,198 · App. 16/435,453 · Granted Nov 15, 2022

Genetically modified mice expressing humanized CD40

Inventors: Yuelei Shen (Beijing, CN); Chaoshe Guo (Beijing, CN); Rui Huang (Beijing, CN); Lei Zhao (Beijing, CN); Yanan Guo (Beijing, CN); Yang Bai (Beijing, CN); Meiling Zhang (Beijing, CN); Jiawei Yao (Beijing, CN)
Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
A01K67/0278A01K2217/072A01K2227/105A01K2267/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,497,198
App. No.
16/435,453
Granted
Nov 15, 2022
Kind
B2
Abstract

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD40, and methods of use thereof.

Claims (6)

1. A genetically-modified mouse whose genome comprises a sequence encoding a humanized CD40 at the endogenous CD40 gene locus under the control of endogenous regulatory elements, wherein the humanized CD40 comprises the amino acid sequence as set forth in SEQ ID NO: 27, wherein the mouse expresses a humanized CD40 comprising a humanized extracellular region and an endogenous cytoplasmic region.

2. The mouse of claim 1 , wherein the mouse comprises a homozygous deletion of the endogenous mouse CD40 gene, and the mouse does not express mouse CD40.

3. A method of determining effectiveness of an anti-CD40 antibody for treating cancer, comprising:

administering the anti-CD40 antibody to the mouse of claim 1 , wherein the mouse has a tumor; and

determining inhibitory effects of the anti-CD40 antibody to the tumor.

4. The mouse of claim 1 , wherein the mouse further comprises a sequence encoding a human or chimeric Programmed Cell Death Protein 1 (PD-1) or a human or chimeric Programmed Cell Death 1 Ligand 1 (PD-L1).

Assignments (2)
CHANGE OF NAME Recorded Jan 22, 2021
From: BEIJING BIOCYTOGEN CO., LTD
To: BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Reel/Frame 055087/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2019
From: SHEN, YUELEI; GUO, CHAOSHE; HUANG, RUI; ZHAO, LEI; GUO, YANAN; BAI, YANG; ZHANG, MEILING; YAO, JIAWEI
To: BEIJING BIOCYTOGEN CO., LTD.
Reel/Frame 050616/0907 →
Priority Claims (3)
CN 201710464564.4 · Jun 19, 2017 · national
CN 201710872886.2 · Sep 25, 2017 · national
CN 201810622839.7 · Jun 15, 2018 · national
Continuity (2)
Continuation PCTCN2018091845 · Jun 19, 2018
Related Publication 20190343098A1 · Nov 14, 2019